Venus Remedies Expands In Philippines, Morocco With Oncology Drug Approvals

Venus Remedies, an oncology drug manufacturer, has obtained marketing authorisations for two essential cancer treatments. 

The company in a press statement on Tuesday informed that the approvals include bortezomib in the Philippines and carboplatin in Morocco, further expanding the company’s oncology portfolio to 508 approvals across 76 countries.

“These approvals are pivotal in our strategy to expand our oncology range and meet the increasing global demand for cancer treatments,” stated Saransh Chaudhary, President of Global Critical Care at Venus Remedies. He added that the company is moving closer to its goal of becoming a leading oncology drug supplier in Southeast Asia.

The Philippine market, the second-largest in the ASEAN region, is poised for significant growth, with projections estimating it to rise from USD 400 million in 2022 to USD 790 million by 2030. The recent approval of bortezomib will enable Venus Remedies to cater to this expanding demand for advanced cancer treatments in Southeast Asia.

In Morocco, where the oncology drug market is expected to reach USD 150.8 million by 2029, the approval of carboplatin will enhance the company’s presence in the African region.

Aditi K. Chaudhary, President of International Business, highlighted the company’s commitment to global healthcare. “These authorisations reflect our dedication to providing innovative and accessible healthcare solutions worldwide,” she noted.

These milestones align with India’s rising pharmaceutical exports, which totalled US2D 7.9 billion in the 2023-24 fiscal year. The global oncology market is also set to expand, projected to reach USD 518.25 billion by 2032.